Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2022 | BEGONIA: durvalumab + dato-DXd in advanced TNBC

Yeon Hee Park, MD, PhD, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, discusses the results of the BEGONIA study (NCT03742102), an ongoing two-part, open-label platform study evaluating durvalumab combined with other therapies, including antibody-drug conjugates in first-line advanced or metastatic triple-negative breast cancer (TNBC). In this update, the use of durvalumab in combination with datopotamab deruxtecan (dato-DXd) demonstrated robust response rates with a manageable safety profile. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.